|
1
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stryker SJ, Wolff BG, Culp CE, Libbe SD,
Ilstrup DM and MacCarty RL: Natural history of untreated colonic
polyps. Gastroenterology. 93:1009–1013. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Butterworth AS, Higgins JP and Pharoah P:
Relative and absolute risk of colorectal cancer for individuals
with a family history: A meta-analysis. Eur J Cancer. 42:216–227.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valle L: Genetic predisposition to
colorectal cancer: Where we stand and future perspectives. World J
Gastroenterol. 20:9828–9849. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Danese E and Montagnana M: Epigenetics of
colorectal cancer: Emerging circulating diagnostic and prognostic
biomarkers. Ann Transl Med. 5:2792017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pancione M, Remo A and Colantuoni V:
Genetic and epigenetic events generate multiple pathways in
colorectal cancer progression. Patholog Res Int 2012.
5093482012.
|
|
7
|
Jafri MA, Al-Qahtani MH and Shay JW: Role
of miRNAs in human cancer metastasis: Implications for therapeutic
intervention. Semin Cancer Biol. 44:117–131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peng Y and Croce CM: The role of MicroRNAs
in human cancer. Signal Transduct Target Ther. 1:150042016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pratt AJ and MacRae IJ: The RNA-induced
silencing complex: A versatile gene-silencing machine. J Biol Chem.
284:17897–17901. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai X and Cullen BR: The imprinted H19
noncoding RNA is a primary microRNA precursor. RNA. 13:313–316.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hao Y, Crenshaw T, Moulton T, Newcomb E
and Tycko B: Tumour-suppressor activity of H19 RNA. Nature.
365:764–767. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yan J, Zhang Y, She Q, Li X, Peng L, Wang
X, Liu S, Shen X, Zhang W, Dong Y, et al: Long noncoding RNA
H19/miR-675 axis promotes gastric cancer via FADD/caspase 8/caspase
3 signaling pathway. Cell Physiol Biochem. 42:2364–2376. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li H, Li J, Jia S, Wu M, An J, Zheng Q,
Zhang W and Lu D: miR675 upregulates long noncoding RNA H19 through
activating EGR1 in human liver cancer. Oncotarget. 6:31958–31984.
2015.PubMed/NCBI
|
|
14
|
Wang J, Zhao YC, Lu YD and Ma CP:
Integrated bioinformatics analyses identify dysregulated miRNAs in
lung cancer. Eur Rev Med Pharmacol Sci. 18:2270–2274.
2014.PubMed/NCBI
|
|
15
|
Sugiyama T, Frazier DP, Taneja P, Morgan
RL, Willingham MC and Inoue K: Role of DMP1 and its future in lung
cancer diagnostics. Expert Rev Mol Diagn. 8:435–447. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inoue K, Zindy F, Randle DH, Rehg JE and
Sherr CJ: Dmp1 is haplo-insufficient for tumor suppression and
modifies the frequencies of Arf and p53 mutations in Myc-induced
lymphomas. Genes Dev. 15:2934–2939. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, Olsson I, et al: Proteomics. Tissue-based
map of the human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kobayashi M and Srour EF: Regulation of
murine hematopoietic stem cell quiescence by Dmtf1. Blood.
118:6562–6571. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015. View Article : Google Scholar
|
|
21
|
Peng Y, Dong W, Lin TX, Zhong GZ, Liao B,
Wang B, Gu P, Huang L, Xie Y, Lu FD, et al: MicroRNA-155 promotes
bladder cancer growth by repressing the tumor suppressor DMTF1.
Oncotarget. 6:16043–16058. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu S, Mott RT, Fry EA, Taneja P, Kulik G,
Sui G and Inoue K: Cooperation between Dmp1 loss and cyclin D1
overexpression in breast cancer. Am J Pathol. 183:1339–1350. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nervi C, De Marinis E and
Codacci-Pisanelli G: Epigenetic treatment of solid tumours: A
review of clinical trials. Clin Epigenetics. 7:1272015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Santini V, Melnick A, Maciejewski JP,
Duprez E, Nervi C, Cocco L, Ford KG and Mufti G: Epigenetics in
focus: Pathogenesis of myelodysplastic syndromes and the role of
hypomethylating agents. Crit Rev Oncol Hematol. 88:231–245. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fakih MG, Pendyala L, Fetterly G, Toth K,
Zwiebel JA, Espinoza-Delgado I, Litwin A, Rustum YM, Ross ME,
Holleran JL and Egorin MJ: A phase I, pharmacokinetic and
pharmacodynamic study on vorinostat in combination with
5-fluorouracil, leucovorin, and oxaliplatin in patients with
refractory colorectal cancer. Clin Cancer Res. 15:3189–3195. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fakih MG, Fetterly G, Egorin MJ, Muindi
JR, Espinoza-Delgado I, Zwiebel JA, Litwin A, Holleran JL, Wang K
and Diasio RB: A phase I, pharmacokinetic, and pharmacodynamic
study of two schedules of vorinostat in combination with
5-fluorouracil and leucovorin in patients with refractory solid
tumors. Clin Cancer Res. 16:3786–3794. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wilson PM, El-Khoueiry A, Iqbal S, Fazzone
W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M,
et al: A phase I/II trial of vorinostat in combination with
5-fluorouracil in patients with metastatic colorectal cancer who
previously failed 5-FU-based chemotherapy. Cancer Chemother
Pharmacol. 65:979–988. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Azad NS, El-Khoueiry A, Yin J, Oberg AL,
Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P,
et al: Combination epigenetic therapy in metastatic colorectal
cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: A
phase 2 consortium/stand up 2 cancer study. Oncotarget.
8:35326–35338. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sreeramaneni R, Chaudhry A, McMahon M,
Sherr CJ and Inoue K: Ras-Raf-Arf signaling critically depends on
the Dmp1 transcription factor. Mol Cell Biol. 25:220–232. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Inoue K and Sherr CJ: Gene expression and
cell cycle arrest mediated by transcription factor DMP1 is
antagonized by D-type cyclins through a
cyclin-dependent-kinase-independent mechanism. Mol Cell Biol.
18:1590–1600. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Macha MA, Seshacharyulu P, Krishn SR, Pai
P, Rachagani S, Jain M and Batra SK: MicroRNAs (miRNAs) as
biomarker(s) for prognosis and diagnosis of gastrointestinal (GI)
cancers. Curr Pharm Des. 20:5287–5297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schmitz KJ, Helwig J, Bertram S, Sheu SY,
Suttorp AC, Seggewiss J, Willscher E, Walz MK, Worm K and Schmid
KW: Differential expression of microRNA-675, microRNA-139-3p and
microRNA-335 in benign and malignant adrenocortical tumours. J Clin
Pathol. 64:529–535. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schultz NA, Andersen KK, Roslind A,
Willenbrock H, Wøjdemann M and Johansen JS: Prognostic microRNAs in
cancer tissue from patients operated for pancreatic cancer-five
microRNAs in a prognostic index. World J Surg. 36:2699–2707. 2012.
View Article : Google Scholar : PubMed/NCBI
|
